C P Tiefenbacher. Show Affiliations »
Abstract
Entities: Chemical Gene
Mesh: See more » AnimalsArginine/administration & dosageBiopterin/administration & dosageBiopterin/analogs & derivativesBiopterin/metabolismCardiovascular Diseases/drug therapyCardiovascular Diseases/metabolismCardiovascular Diseases/physiopathologyClinical Trials as TopicCoronary Vessels/drug effectsCoronary Vessels/metabolismDogsEndothelium, Vascular/drug effectsEndothelium, Vascular/metabolismEndothelium, Vascular/physiopathologyEnzyme Inhibitors/administration & dosageHistamine/pharmacologyHumansHypercholesterolemia/drug therapyHypercholesterolemia/metabolismIn Vitro TechniquesInfusions, Intra-ArterialIonophores/pharmacologyNitric Oxide/metabolismNitric Oxide Synthase/antagonists & inhibitorsNitric Oxide Synthase/metabolismNitric Oxide Synthase Type IIIPteridines/metabolismPteridines/therapeutic usePterinsReactive Oxygen Species/metabolismSpecies SpecificitySubstance P/pharmacologySwineVasoconstrictor Agents/administration & dosageVasodilator Agents/therapeutic useomega-N-Methylarginine/administration & dosage
Substances: See more » Enzyme InhibitorsIonophoresPteridinesPterinsReactive Oxygen SpeciesVasoconstrictor AgentsVasodilator AgentsBiopterinomega-N-MethylarginineNitric OxideSubstance PHistamineArgininesepiapterinNOS3 protein, humanNitric Oxide SynthaseNitric Oxide Synthase Type IIIsapropterin
Year: 2001 PMID: 11356602 DOI: 10.1152/ajpheart.2001.280.6.H2484
Source DB: PubMed Journal: Am J Physiol Heart Circ Physiol ISSN: 0363-6135 Impact factor: 4.733